Loading
CD30 is a protein on the malignant Reed-Sternberg cells of Hodgkin lymphoma and on some T-cell lymphomas, and the address for the ADC brentuximab vedotin. This dossier gathers the 1 product (0 approved), 4 trials, 0 pathways and 1 resistance route in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Signals via TRAF proteins to NF-κB; shed soluble CD30 is a serum marker. Sparse normal expression outside activated T and B cells.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Hodgkin lymphoma | 100% | IHC; CD30 is a defining feature of Hodgkin Reed-Sternberg cells | Hu 2013 (Blood); classical Hodgkin lymphoma is CD30-positive by definition | doi.org |
| Diffuse large B-cell lymphoma | 14% | IHC, CD30 in 903 de novo DLBCL | Hu 2013; CD30-positive DLBCL had better outcome and a distinct gene-expression signature | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Phase 2 |
|---|---|
| Cell therapy 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | Median overall survival 13.8 against 8.5 months (hazard ratio 0.63, two-sided p = 0.009) and median progression-free survival 4.2 against 2.6 months (hazard ratio 0.53). | ||
ECHELON-1 NCT01712490 | 3 | Positive | Untreated stage III-IV classical Hodgkin lymphoma: brentuximab vedotin + AVD vs ABVD | 6-year OS 93.9% vs 89.4%, HR 0.59. | |
RADAR NCT04685616 | 3 | Active | Untreated early-stage classical Hodgkin lymphoma: ABVD against A2VD, which replaces the bleomycin with brentuximab vedotin, with treatment after two cycles set by a centrally reviewed scan | - | |
| 1/2 | Recruiting | A Phase 1/2, Open-Label, Target-Selected Study of Allogeneic CAR-NK Cells Directed to CD30, CD5, or Mesothelin in Patients With Relapsed/Refractory B2 Thymoma or Thymic Carcinoma | - |
Hodgkin lymphoma responds despite deficient MHC class I. Across the CheckMate 205 biopsies, class I and beta-2-microglobulin did not predict complete remission but class II did, which points at a CD4 T cell as the effector and makes class II loss the escape route.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"CD30" OR ABSTRACT:"CD30" OR TITLE:"TNFRSF8" OR ABSTRACT:"TNFRSF8") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD30, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/cd30.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/cd30.json. Licence CC BY-NC 4.0.